@article {2122, title = {Knowledge and Perception of the Risk of Respiration Disorders in COVID-19 Pandemic in COPD Patient: A Mixed-Method Study}, journal = {Pharmacognosy Journal}, volume = {15}, year = {2023}, month = {October 2023}, pages = {801-810}, chapter = {801}, abstract = {

Introduction: Chronic obstructive pulmonary disease (COPD) have a higher risk for COVID-19-related complications. Knowledge and perception will greatly influence the behavior of a COPD patient in dealing with a problem, such as the risk of COVID-19 infection. The purpose of the study was to determine knowledge and perceptions about the risk of respiration disorders during the COVID-19 pandemic in COPD patients. This research was a mixed methods research with an explanatory sequential research design. The location was conducted in Rungkut District in Surabaya City, East Java, from May-October 2022. Sampling by purposive sampling method, and analyzed descriptively. The research sample was 116 people. On the knowledge, the most correct answers were the COVID-19 virus was contagious (112 of 116). On the perception, the answer with the most positive level is a question regarding the use of masks. Some respondents had a low knowledge category (54 of 116), and the most positive perception category (57 of 116). The respondents{\textquoteright} knowledge of the COVID-19 virus showed COVID-19 virus was a contagious disease and was transmitted through air. But many respondents didn{\textquoteright}t know about the type of COVID-19 virus. Therefore, it was necessary to develop a strategy to increase knowledge about COVID-19 and related COPD treatment.

}, keywords = {COPD, COVID-19, knowledge, Perception.}, doi = {10.5530/pj.2023.15.155}, author = {Amelia Lorensia and Rivan Virlando Suryadinata and Dita Sukmaya Prawitasari} } @article {1926, title = {Kaempferia galanga L. Extract Administration Attenuate Aquaporin-4 Expression in Traumatic Brain Injury: An Experimental Study in Rats}, journal = {Pharmacognosy Journal}, volume = {14}, year = {2022}, month = {January 2023}, pages = {893-897}, type = {Original Article }, chapter = {893}, abstract = {

Introduction: Traumatic brain injury (TBI) is still a major health problem in the world. It might cause long-term disability that affect socio-economic life and become nation health burden. Post-traumatic cerebral edema might develop and commit to an unfavorable prognosis. Aquaporin 4 (AQP4) is water channel protein and a key regulator of water metabolism in the brain. Although the mechanism of AQP4 in the regulation of post-traumatic brain edema remains controversial, AQP4-lacking mice show better survival and decreased brain edema. Thus, novel strategies that suppress AQP4 become a potential field. We hypothesized that Kaempferia galanga L. may suppress brain expression of AQP4 following TBI and possibly limit the development of cerebral edema due to its neuroinflammation properties. Method: We conducted TBI to experimental rats, then given Kaempferia galanga L. extract at a dose of 600 mg/kg BW and 1200 mg/kg BW. Evaluation intensity of AQP4 expression by immunohistochemistry was performed 24 and 48 hours later to see its therapeutic effect. Results: Administration of Kaempferia galanga L. extract at a dose of 1200 mg/kg BW showed weak expression of AQP4 in all samples, both 24 and 48 hours following traumatic brain injury treatment. Conclusions: Intensity of AQP4 expression in rats{\textquoteright} brain was lower at 24 and 48 hours after TBI in rats receiving Kaempferia galanga L. extract with dose 1200 mg/ kg BW compared to the other groups. Our result indicates that Kaempferia galanga L. might affect the expression of brain AQP4 in a dose-dependent manner.

}, keywords = {Ayuverdic medicine, Neuroinflammation, Neurotrauma, Post-traumatic cerebral edema}, doi = {10.5530/pj.2022.14.185}, author = {Fajar Herbowo Niantiarno and Agus Turchan and Myrna Adianti and Budi Utomo and Muhammad Arifin Parenrengi and Abdul Hafid Bajamal} } @article {1844, title = {Knowledge and Awareness about Pharmacogenomics and Personalized Medicine Among the Students of College of Medicine, Shaqra university in Dawadmi, Kingdom of Saudi Arabia}, journal = {Pharmacognosy Journal}, volume = {14}, year = {2022}, month = {August 2022}, pages = {367-372}, type = {Research Article }, chapter = {367}, abstract = {

Introduction: Pharmacogenomics and personalized medicine are the two rapidly emerging areas in medical field which will determine the drug therapy of the future. It is very important for current medical students to be aware of these medical fields and apply these principles in their medical practice. There is huge scope for research in this area, hence an awareness study was conducted among medical students of college of medicine, Shaqra university, Dawadmi. Methods: A cross sectional questionnaire-based study was conducted among the medical students of Shaqra university, Dawadmi by self-administered questionnaire. 150 students participated in the study. Results: Out of the 150 students participated in the study Pharmacogenomics is relevant to my education 25\% strongly agree. 45\% agreed to recommend pharmacogenomic testing. Familiarity with genetics is only 16\% and only 14\% are familiar with interpreting results of pharmacogenomic tests. Knowledge testing showed overall less percentage. Only 16\% can identify drugs that require pharmacogenomic testing. But 36\% are confident to use the results of pharmacogenomics tests to make an appropriate adjustment to a patient{\textquoteright}s drug therapy. Knowledge about personalized medicine is 31\% with scale of 3 out of 7.40\% of students agreed to undergo genetic testing. 52\% of the participants agreed to know about their risk for developing genetic based chronic diseases. Conclusion: There is genuine interest and awareness about Pharmacogenomics and Personalized medicine among the medical students but the knowledge is lacking. Hence including these areas in the undergraduate medical curriculum will impart valuable knowledge to the future medical students.

}, keywords = {Personalized medicine, Pharmacogenetic testing, Pharmacogenomics}, doi = {10.5530/pj.2022.14.109}, author = {Inbaraj Susai Domnic and Faisal Fahad Al Otaibi and Noureldaim Elnoman Elbadawi and Prasanna Mohana Bhaskaran and Mohammad Azhar Rashikh and Dinesh Dimri} }